NO20026032D0 - Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer - Google Patents

Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer

Info

Publication number
NO20026032D0
NO20026032D0 NO20026032A NO20026032A NO20026032D0 NO 20026032 D0 NO20026032 D0 NO 20026032D0 NO 20026032 A NO20026032 A NO 20026032A NO 20026032 A NO20026032 A NO 20026032A NO 20026032 D0 NO20026032 D0 NO 20026032D0
Authority
NO
Norway
Prior art keywords
annealed
farnesyltransferase inhibiting
quinoline enantiomer
enantiomer
quinoline
Prior art date
Application number
NO20026032A
Other languages
English (en)
Other versions
NO20026032L (no
NO324494B1 (no
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
David William End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20026032L publication Critical patent/NO20026032L/no
Publication of NO20026032D0 publication Critical patent/NO20026032D0/no
Publication of NO324494B1 publication Critical patent/NO324494B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20026032A 2000-06-22 2002-12-16 Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer, farmasoytisk sammensetning inneholdende denne og dens fremstilling, samt anvendelse av forbindelsen NO324494B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (3)

Publication Number Publication Date
NO20026032L NO20026032L (no) 2002-12-16
NO20026032D0 true NO20026032D0 (no) 2002-12-16
NO324494B1 NO324494B1 (no) 2007-10-29

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026032A NO324494B1 (no) 2000-06-22 2002-12-16 Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer, farmasoytisk sammensetning inneholdende denne og dens fremstilling, samt anvendelse av forbindelsen

Country Status (34)

Country Link
US (3) US20030114471A1 (no)
EP (1) EP1296984B1 (no)
JP (1) JP4919575B2 (no)
KR (2) KR100831940B1 (no)
CN (1) CN1207296C (no)
AR (1) AR030704A1 (no)
AT (1) ATE294804T1 (no)
AU (3) AU2001263962B2 (no)
BG (1) BG65894B1 (no)
BR (1) BRPI0111743B8 (no)
CA (1) CA2410232C (no)
CZ (1) CZ295278B6 (no)
DE (1) DE60110592T2 (no)
EA (1) EA005065B1 (no)
EE (1) EE04966B1 (no)
EG (1) EG24180A (no)
ES (1) ES2241830T3 (no)
HK (1) HK1058363A1 (no)
HR (1) HRP20020989B1 (no)
HU (1) HU229095B1 (no)
IL (2) IL153560A0 (no)
IS (1) IS2596B (no)
JO (1) JO2361B1 (no)
MX (1) MXPA02012845A (no)
MY (1) MY127734A (no)
NO (1) NO324494B1 (no)
NZ (1) NZ522481A (no)
PA (1) PA8519501A1 (no)
PL (1) PL209521B1 (no)
SA (1) SA01220349B1 (no)
SK (1) SK285699B6 (no)
UA (1) UA73572C2 (no)
WO (1) WO2001098302A1 (no)
ZA (1) ZA200210305B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
DK3534885T3 (da) 2016-11-03 2021-04-12 Kura Oncology Inc Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
TR199800825T2 (xx) * 1995-12-08 1998-08-21 Janssen Pharmaceutica N.V. Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CN1094937C (zh) * 1997-04-25 2002-11-27 詹森药业有限公司 具抑制法呢基转化酶作用的喹唑啉酮类
EP0988038B1 (en) 1997-06-02 2002-08-14 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
ID27199A (id) 1998-07-06 2001-03-08 Janssen Pharmaceutica Nv Penghambat transferase protein farnesil untuk pengobatan artropatis
IL140721A0 (en) * 1998-07-06 2002-02-10 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
JP3494409B2 (ja) * 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
SK2442001A3 (en) * 1998-08-27 2002-10-08 Pfizer Prod Inc Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof
KR100818541B1 (ko) * 1998-12-23 2008-04-02 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
TR200201297T2 (tr) * 1999-02-11 2002-06-21 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Also Published As

Publication number Publication date
CN1207296C (zh) 2005-06-22
US20030114471A1 (en) 2003-06-19
ES2241830T3 (es) 2005-11-01
CZ295278B6 (cs) 2005-06-15
ZA200210305B (en) 2004-03-19
CA2410232C (en) 2008-10-07
US20070259902A1 (en) 2007-11-08
US8329714B2 (en) 2012-12-11
AU6396201A (en) 2002-01-02
EG24180A (en) 2008-09-28
MY127734A (en) 2006-12-29
AU2006220405A1 (en) 2006-10-12
HUP0300872A3 (en) 2004-11-29
CZ2003114A3 (cs) 2003-05-14
HK1058363A1 (en) 2004-05-14
US20080114009A1 (en) 2008-05-15
EA005065B1 (ru) 2004-10-28
ATE294804T1 (de) 2005-05-15
HU229095B1 (en) 2013-07-29
IS2596B (is) 2010-03-15
IS6590A (is) 2002-10-25
AR030704A1 (es) 2003-09-03
DE60110592T2 (de) 2006-01-19
EA200300048A1 (ru) 2003-04-24
SK285699B6 (sk) 2007-06-07
HRP20020989B1 (en) 2011-05-31
PL209521B1 (pl) 2011-09-30
NZ522481A (en) 2004-09-24
WO2001098302A1 (en) 2001-12-27
BRPI0111743B8 (pt) 2021-05-25
PL358918A1 (en) 2004-08-23
CN1437601A (zh) 2003-08-20
SK502003A3 (en) 2003-05-02
AU2001263962B2 (en) 2006-07-20
NO20026032L (no) 2002-12-16
EP1296984A1 (en) 2003-04-02
HUP0300872A2 (hu) 2003-07-28
SA01220349B1 (ar) 2007-01-23
KR100831940B1 (ko) 2008-05-23
KR20070121847A (ko) 2007-12-27
MXPA02012845A (es) 2003-05-15
AU2006220405B2 (en) 2009-05-21
BRPI0111743B1 (pt) 2019-03-26
EE200200695A (et) 2004-06-15
BR0111743A (pt) 2003-07-08
CA2410232A1 (en) 2001-12-27
EE04966B1 (et) 2008-02-15
IL153560A (en) 2011-06-30
NO324494B1 (no) 2007-10-29
KR20030009463A (ko) 2003-01-29
IL153560A0 (en) 2003-07-06
JO2361B1 (en) 2006-12-12
KR100846370B1 (ko) 2008-07-15
EP1296984B1 (en) 2005-05-04
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
BG107310A (bg) 2003-07-31
HRP20020989A2 (en) 2005-02-28
BG65894B1 (bg) 2010-04-30
PA8519501A1 (es) 2002-08-29
UA73572C2 (en) 2005-08-15
JP4919575B2 (ja) 2012-04-18
US8318753B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
RS51123B (sr) Aril fuzionisana azapoliciklična jedinjenja
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására
TH59553B (th) 1,2-แอนเนเลเทด ควิโนลีน อิแนนซิโอเมอร์ ซึ่งมีฤทธิ์ยับยั้งฟาร์เนซิลทรานส์เฟอเรส
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
MK1K Patent expired